Merck & Co., Inc.MRKNYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank36
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P36
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -12.80% |
| Q3 2025 | 4.59% |
| Q2 2025 | 11.79% |
| Q1 2025 | -21.01% |
| Q4 2024 | -21.80% |
| Q3 2024 | 67.49% |
| Q2 2024 | -12.32% |
| Q1 2024 | -58.53% |
| Q4 2023 | 191.11% |
| Q3 2023 | -75.17% |
| Q2 2023 | 211.53% |
| Q1 2023 | 13.27% |
| Q4 2022 | -14.19% |
| Q3 2022 | 57.22% |
| Q2 2022 | 8.62% |
| Q1 2022 | -16.04% |
| Q4 2021 | 25.48% |
| Q3 2021 | -43.42% |
| Q2 2021 | 79.15% |
| Q1 2021 | -58.68% |
| Q4 2020 | 74.29% |
| Q3 2020 | 60.62% |
| Q2 2020 | -5.61% |
| Q1 2020 | -13.30% |
| Q4 2019 | -20.47% |
| Q3 2019 | 46.37% |
| Q2 2019 | 13.36% |
| Q1 2019 | -12.78% |
| Q4 2018 | 7.06% |
| Q3 2018 | -9.06% |
| Q2 2018 | -28.85% |
| Q1 2018 | 40.11% |
| Q4 2017 | -48.31% |
| Q3 2017 | 147.64% |
| Q2 2017 | -2.62% |
| Q1 2017 | -60.64% |
| Q4 2016 | 179.39% |
| Q3 2016 | -22.64% |
| Q2 2016 | 29.66% |
| Q1 2016 | -7.73% |